Sermorelin is the oldest analog of human GHRH on the compounded peptide menu — synthesized in the late 1970s, FDA-approved as Geref for pediatric growth-hormone-deficiency diagnosis in 1997, and prescribed continuously in adult anti-aging practice since the early 2000s. In the 2026 Limitless protocol it occupies a deliberately specific role: the standing alternative GHRH analog — used where tesamorelin is contraindicated, unavailable, or cost-sensitive, and as the de facto formulary backbone if either of two regulatory dominoes falls the wrong way later this year.
This brief explains why. It is the evidence companion to the tesamorelin GH-axis evidence brief, and the two should be read as a pair — they describe the same menu from two different positions.
The shape of the evidence base.
Sermorelin's evidence base is shaped differently from tesamorelin's. Tesamorelin has a pivotal 26-week trial, a 2026 pooled meta-analysis, and an emerging cognitive endpoint. Sermorelin has decades of small-to-medium clinical trials, classical GHRH-stimulation studies, and a long real-world track record in adult anti-aging practice. The signal is consistent but the trial sample sizes are smaller, the indications are broader, and almost none of the modern trials are conducted under contemporary clinical-trial standards.
Three trials are load-bearing for the Limitless prescribing posture:
Khorram 1997 — short-course GHRH in healthy older adults
Khorram and colleagues administered a GHRH analog at 10 mcg/kg subcutaneously twice daily for 16 weeks to healthy adults 64–76 years old. The trial reported restored GH pulse amplitude, increased IGF-1 into a healthy young-adult range, and an improvement in lean body mass and skin thickness measured by DEXA. The blood pressure, glucose, and HbA1c trajectories stayed inside the physiologic envelope. It was small (n=26), but the dose-response was clean.
Vittone 1997 — six-week GHRH in older men
Vittone and colleagues reported a 6-week trial of GHRH 1–29 at 10 mcg/kg subcutaneously nightly in older men. The trial measured body composition by DEXA, IGF-1 by RIA, and reported a statistically significant increase in IGF-1 and a measurable, though modest, increase in lean mass and decrease in fat mass. The trial is mechanistically informative because the trajectory of IGF-1 over six weeks tracks closely with the predicted GHRH pulse-amplitude curve — exactly the relationship that should hold if the molecule is doing what it says on the label.
Walker 2006 — long-term sermorelin safety
Walker and colleagues followed adults receiving sermorelin acetate in clinical practice for longitudinal endpoints. The headline finding for prescribers is the safety profile: no signal of malignancy excess, no signal of diabetes induction, no signal of fluid retention beyond what's expected on a GHRH analog at therapeutic doses. The trial is methodologically imperfect — long-term real-world data nearly always are — but it provides the safety baseline that justifies continued use in healthy adults at standard doses.
Those three trials are not, by themselves, a tesamorelin-equivalent dossier. They are something different: the basis for a long, durable presumption of safety and biological activity. That is the use case sermorelin is fit for at Limitless.
Where sermorelin sits — exactly — in the menu.
The 2026 Limitless GH-axis menu has four tiers. Sermorelin is one of them; understanding the shape of the menu makes the role of sermorelin clearer than reading about sermorelin alone.
| Option | Posture | Why |
|---|---|---|
| Tesamorelin | Lead | Only FDA-approved GHRH analog. 26-week pivotal trial. Pooled meta-analysis: −27.7 cm² VAT, +1.42 kg lean mass. Emerging cognitive endpoint. |
| Sermorelin | Alternative | Long real-world record. Walker 2006 safety, Khorram 1997 + Vittone 1997 efficacy signals. Lower per-month cost typically than tesamorelin. Available where tesamorelin is not. |
| Ipamorelin | Conditional | Back on formulary post-April 23, 2026. On the July 23 PCAC docket. Add only after verifying 503A partner pharmacy formulary at the time of prescribing. |
| CJC-1295 (No DAC) | Off the menu | Referred to PCAC after April 2026. Not on the July 23 docket. Not currently legal for human compounding in 2026. Full rulemaking required before lawful compounding can resume. See our filed FDA comment. |
What this means in practice: a Limitless patient evaluated for the GH-axis intervention defaults to tesamorelin. If tesamorelin is contraindicated, unavailable, or financially out of reach, sermorelin is the named alternative — not a degraded substitute, but a different point on the GHRH-analog spectrum with its own evidence shape. Ipamorelin can be added on top of either as a GHS adjunct where formulary allows. CJC-1295 is not used.
The substitution rules.
Sermorelin substitutes for tesamorelin in five specific situations at Limitless. We name them so they're not improvised on a case-by-case basis:
- Tesamorelin contraindicated. Patient with active malignancy, severe diabetic retinopathy, or hypersensitivity history. The contraindications listed in the Egrifta label carry forward to the off-label use.
- Tesamorelin unavailable. Branded supply gap; compounded tesamorelin not available through the patient's 503A partner pharmacy; international travel for an extended period that complicates supply.
- Cost-sensitivity. Sermorelin is typically less expensive per treatment month than tesamorelin (branded or compounded). For the right patient — older adult on a fixed income, multi-protocol patient managing total monthly spend — sermorelin is the right molecule for the right reason.
- Lower-magnitude target. A patient whose primary indication is a modest GH-axis tune-up rather than a clinically meaningful visceral-adiposity reduction is often well-served by sermorelin's smaller, durable signal.
- Transition plan. A patient cycling off tesamorelin who wants to maintain a smaller-amplitude GH-axis support during the off-cycle.
What sermorelin does not substitute for: a tesamorelin-strength visceral-adiposity reduction, an HIV-associated lipodystrophy indication where the FDA-approved option exists, or a research-grade cognitive endpoint (those data are anchored to tesamorelin / GHRH at higher doses, not to sermorelin specifically). If the clinical target is one of those, the right move is to fix the tesamorelin access problem, not to silently downshift to sermorelin.
The Limitless sermorelin protocol.
Standing sermorelin dosing
Dose: 200–500 mcg subcutaneous injection nightly, typically 5 nights on / 2 off, rotating injection sites.
Initial assessment window: 12 weeks. Reassessment of IGF-1, body composition, symptom domain.
Lab monitoring: Baseline IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel. Repeat at week 8 and week 12.
Cycle structure: Continuous or cyclic dosing both supported. The cycle plan is set at consultation, not boilerplate.
Stacked use: Where ipamorelin is on the 503A partner formulary, ipamorelin can be added as a GHS adjunct to sermorelin on the same nightly injection. The combined GHRH-plus-GHS approach amplifies the GH pulse more than either alone.
What changes after July 23, 2026.
The July 23–24 PCAC meeting does not have sermorelin on the agenda. It does have BPC-157, TB-500, KPV, and MOTS-c on day one, and DSIP and Semax on day two. Sermorelin sits outside that review entirely — which is itself a meaningful regulatory data point. The agency is not actively scrutinizing sermorelin's compounding status, and there is no public signal of a restriction coming.
Two outcomes from that meeting would directly affect the sermorelin posture:
- Ipamorelin posture changes. If ipamorelin's regulatory posture shifts (in either direction), sermorelin becomes either more useful as a standalone (if ipamorelin restricted) or more redundant in a stack (if ipamorelin freely available). The standing protocol absorbs either move without rewriting.
- Tesamorelin supply tightening. A counterintuitive risk: heightened regulatory attention to the compounded peptide space can ripple to compounded tesamorelin availability through 503A pharmacies, even though branded Egrifta is unaffected. If that happens, sermorelin's role expands from "alternative" to "primary fallback" for patients who can't access branded supply.
In either case, the brief gets revised here transparently rather than silently in the back end of a patient chart.
The summary.
Sermorelin is on the Limitless menu because the evidence base — Walker 2006 long-term safety, Khorram 1997 and Vittone 1997 mechanistic-and-efficacy signals — supports continued use as the alternative GHRH analog. It does not displace tesamorelin as the lead. It does not substitute for the specific things tesamorelin is best at. It does occupy a clinically meaningful role for the right patient, at the right cost, in the right access situation. And in a regulatory environment where the GH-axis menu has shifted twice in two months, the molecule with the longest, most boring safety record is exactly the molecule worth having on the bench.
If you are a Limitless patient and your protocol includes sermorelin, the reasoning above is the reasoning behind that choice. If you are a Limitless patient and your protocol does not include sermorelin, the same reasoning likely applies in reverse — tesamorelin was the better-fit molecule for your phenotype, your indication, or both.
Signed,
Joshua Hare, DO
Founder & Medical Director, Limitless Performance Medicine